Alzamend Neuro (ALZN) Other Working Capital Changes (2020 - 2026)
Alzamend Neuro's (ALZN) quarterly Other Working Capital Changes came in at $67665.0 in Q2 2026, up 118.77% year-over-year from $30929.7 in Q2 2025, and down 90.52% quarter-over-quarter from $714128.0 in Q1 2026.
Powered by 
Analysis
Alzamend Neuro (ALZN) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Alzamend Neuro has disclosed Other Working Capital Changes across 7 years of filings, most recently posting $67665.0 for Q2 2026.
- In Q2 2026, Other Working Capital Changes rose 118.77% year-over-year to $67665.0; the TTM figure through Apr 2026 stood at $825089.0 (up 451.81% YoY), while the FY2026 annual figure was $825089.0, up 451.81% from the prior year.
- Other Working Capital Changes came in at $67665.0 for Q2 2026 at Alzamend Neuro, down from $714128.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $714128.0 in Q1 2026 to a low of -$360489.0 in Q2 2025.
- Average Other Working Capital Changes over 5 years is $6978.0, with a median of -$60202.0 recorded in 2025.
- Year-over-year, Other Working Capital Changes tumbled 298.25% in 2024 and jumped 945.51% in 2026.
- Over 5 years, Other Working Capital Changes stood at -$177968.0 in 2022, then grew by 23.36% to -$136386.0 in 2023, then surged by 430.99% to $451428.0 in 2024, then slumped by 107.96% to -$35943.0 in 2025, then surged by 288.26% to $67665.0 in 2026.
- Per Business Quant data, the three most recent Other Working Capital Changes figures were $67665.0 in Q2 2026, $714128.0 in Q1 2026, and -$35943.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Alzamend Neuro | 5.54 Mn | 5.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 67,665.00 |
| Apr 30, 2026 | 67,665.00 |
| Jan 31, 2026 | 714,128.00 |
| Jan 31, 2026 | 714,128.00 |
| Oct 31, 2025 | -35,943.00 |
| Oct 31, 2025 | -35,943.00 |
| Jul 31, 2025 | 79,239.00 |
| Jul 31, 2025 | 79,239.00 |
| Apr 30, 2025 | -360,489.00 |
| Apr 30, 2025 | -360,489.00 |
| Jan 31, 2025 | -84,461.00 |
| Jan 31, 2025 | -84,461.00 |
| Oct 31, 2024 | 451,428.00 |
| Oct 31, 2024 | 451,428.00 |
| Jul 31, 2024 | 143,047.00 |
| Jul 31, 2024 | 143,047.00 |
| Apr 30, 2024 | -231,544.00 |
| Apr 30, 2024 | -231,544.00 |
| Jan 31, 2024 | -271,064.00 |
| Jan 31, 2024 | -271,064.00 |